3/10
07:37 am
bntc
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
Medium
Report
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
3/10
07:00 am
bntc
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
Low
Report
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc
3/9
04:05 pm
bntc
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by TD Cowen.
3/9
12:42 pm
bntc
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Benitec Biopharma (BNTC) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
3/9
07:32 am
bntc
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [Yahoo! Finance]
Low
Report
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference [Yahoo! Finance]
3/9
07:00 am
bntc
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Medium
Report
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2/23
07:00 am
bntc
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Low
Report
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
2/12
08:30 am
bntc
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Medium
Report
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
1/31
04:42 am
bntc
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]
Low
Report
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]